Discussing the Growing Role of CDMOs with Anil Kane (DCAT 2023)
Anil Kane, executive director, Global Head of Technical & Scientific Affairs at Thermo Fisher Scientific, discusses the growing role of CDMOs in the biopharma industry
As part of ongoing coverage of DCAT, the PharmTech editors touched base with Anil Kane, executive director, Global Head of Technical & Scientific Affairs at Thermo Fisher Scientific. In in our discussion, Anil discussed various topics within the outsourcing market, including:
- The increased interest in technologies like cell and gene therapies and oral biologics
- The continued rise of the "end-to-end" CDMO model and why biopharma partners are seeking it out
- Recent investments made in new spaces by Thermo Fisher Scientific
For more of our coverage on DCAT in 2023, viewers can visit this page.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
